BRAIN and NERVE－神経研究の進歩76巻10号

2024年10月発行

特集 どうして効くんだろう

B細胞療法—多発性硬化症

著者： 宮﨑雄生¹² 新野正明²

所属機関： ¹国立病院機構北海道医療センター脳神経内科 ²国立病院機構北海道医療センター臨床研究部

ページ範囲：P.1101 - P.1108

文献概要

抗CD20抗体を用いたB細胞療法は，多発性硬化症の再発を強力に抑制することから重要な治療選択肢の1つとなった。B細胞は炎症性サイトカイン産生，T細胞への抗原提示を介して多発性硬化症（multiple sclerosis：MS）の再発を惹起すると考えられ，その抑制がB細胞療法の最も重要な作用機序である。一方で，B細胞療法には中枢神経内B細胞の活動抑制を介したMS慢性進行抑制効果も想定されており，新規治療法の開発によりさらなる効果改善が期待されている。

参考文献

1）Aloisi F, Giovannoni G, Salvetti M: Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy. Lancet Neurol 22: 338-349, 2023

2）Brändle SM, Obermeier B, Senel M, Bruder J, Mentele R, et al: Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins. Proc Natl Acad Sci U S A 113: 7864-7869, 2016

3）Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, et al: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47: 707-717, 2000

4）Keegan M, König F, McClelland R, Brück W, Morales Y, et al: Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366: 579-582, 2005

5）Jarius S, König FB, Metz I, Ruprecht K, Paul F, et al: Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis. J Neuroinflammation 14: 171, 2017［doi: 10.1186/s12974-017-0929-z］

6）Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, et al; HERMES Trial Group: B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358: 676-688, 2008

7）Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, et al; OPERA I and OPERA II Clinical Investigators: Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med 376: 221-234, 2017

8）Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, et al; ASCLEPIOS I and ASCLEPIOS II Trial Groups: Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 383: 546-557, 2020

9）Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, et al; ULTIMATE I and ULTIMATE II Investigators: Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med 387: 704-714, 2022

10）Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, et al: Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 67: 452-461, 2010

11）Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, et al: Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 67: 707-714, 2010

12）Miyazaki Y, Niino M: B-cell depletion therapy for multiple sclerosis. Immunol Med 45: 54-62, 2022

13）Duddy M, Niino M, Adatia F, Hebert S, Freedman M, et al: Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 178: 6092-6099, 2007

14）Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, et al: B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 209: 1001-1010, 2012

15）Li R, Rezk A, Miyazaki Y, Hilgenberg E, Touil H, et al; Canadian B cells in MS Team: Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med 7: 310ra166, 2015［doi: 10.1126/scitranslmed.aab4176］

16）Kappos L, Li D, Calabresi P, O'Connor P, Bar-Or A, et al: Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial. Mult Scler 18: 140-141, 2012

17）Bar-Or A, Oliveira EM, Anderson DE, Krieger JI, Duddy M, et al: Immunological memory: contribution of memory B cells expressing costimulatory molecules in the resting state. J Immunol 167: 5669-5677, 2001

T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur J Immunol 40: 2942-2956, 2010

T cells in multiple sclerosis. Cell 175: 85-100. e23, 2018［doi: 10.1016/j.cell.2018.08.011］

20）Miyazaki Y, Niino M: Regulatory B cells in neuroimmunological diseases. Clin Exp Neuroimmunol 11: 156-162, 2020

21）Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, et al; ATAMS Study Group: Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol 13: 353-363, 2014

22）Li R, Patterson KR, Bar-Or A: Reassessing B cell contributions in multiple sclerosis. Nat Immunol 19: 696-707, 2018

23）Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F: Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14: 164-174, 2004

24）Komori M, Lin YC, Cortese I, Blake A, Ohayon J, et al: Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Ann Clin Transl Neurol 3: 166-179, 2016

25）Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, et al; ORATORIO Clinical Investigators: Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376: 209-220, 2017

26）Gibiansky E, Petry C, Mercier F, Günther A, Herman A, et al: Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. Br J Clin Pharmacol 87: 2511-2520, 2021

27）Hauser SL, Bar-Or A, Weber MS, Kletzl H, Günther A, et al: Association of higher ocrelizumab exposure with reduced disability progression in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 10: e200094, 2023［doi: 10.1212/NXI.0000000000200094］

28）Airas L, Bermel RA, Chitnis T, Hartung HP, Nakahara J, et al: A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis. Ther Adv Neurol Disord 17: 17562864241233041, 2024［doi: 10.1177/17562864241233041］

29）Schett G, Mackensen A, Mougiakakos D: CAR T-cell therapy in autoimmune diseases. Lancet 402: 2034-2044, 2023

30）MERCK: Merck Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis　https://www.merckgroup.com/en/news/evobrutinib-phase-lll.html（最終閲覧日: 2024年5月9日）

31）Fischbach F, Richter J, Pfeffer LK, Fehse B, Berger SC, et al: CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med 5: 550-558. e2, 2024［doi: 10.1016/j.medj.2024.03.002］